As research on GLP-1 medications continues to evolve, new studies are providing insights into their potential benefits, risks, and long-term impact on patient care. Below are six recent findings healthcare providers should be aware of, with links to the full research for additional details.
- Lower fracture risk for patients with diabetes: New research found GLP-1 medications were associated with a lower risk of fragility fractures in adults with type 2 diabetes, though the opposite trend was seen in people without diabetes.
- Higher risk of temporary hair loss: Studies suggest GLP-1 users may have an increased risk of non-scarring hair loss, which researchers believe may be related to rapid weight loss and nutritional deficiencies.
- Growing use in younger patients: GLP-1 medications continue to replace bariatric surgery as the most common obesity treatment for adolescents and young adults.
- Potential workplace benefits: Research found GLP-1 use was associated with fewer long-term sickness leave days, likely due to improvements in overall cardiometabolic health.
- Coverage and cost remain challenges: Employers and insurers continue to evaluate the long-term value of GLP-1 coverage as medication costs and reimbursement policies evolve.
- New delivery options are in development: Researchers are evaluating a long-acting semaglutide implant that could improve adherence by reducing dosing to twice yearly, with the potential for annual dosing in the future.
Resource: 6 GLP-1 findings to know